Januvia vs Ozempic
Side-by-side cost comparison based on Medicare Part D data
Januvia
Sitagliptin
Manufactured by Merck
Ozempic
Semaglutide
Manufactured by Novo Nordisk
Januvia costs 68% less per claim than Ozempic ($219.00 vs $685.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Januvia | Ozempic |
|---|---|---|
| Avg Cost Per Claim | $219.00 | $685.00 |
| Total Medicare Spending | $2.7B | $5.0B |
| Total Beneficiaries | 1,560,000 | 1,180,000 |
| Total Claims | 12,480,000 | 7,240,000 |
| Annual Cost/Patient | $1,753.00 | $4,200.00 |
| Year-over-Year Change | -12.3% | +72.5% |
| Generic Available | No | No |
| Patent Expiration | Jul 17, 2026 | Sep 20, 2031 |
| Manufacturer | Merck | Novo Nordisk |
| Condition | Diabetes | Diabetes |
| Generic Name | Sitagliptin | Semaglutide |
Januvia vs Ozempic: What the Data Shows
Januvia (Sitagliptin) and Ozempic (Semaglutide) are both used to treat diabetes. Based on Medicare Part D data, Januvia costs $219.00 per claim, which is 68% less than Ozempic at $685.00 per claim.
Medicare spent $2.7B on Januvia and $5.0B on Ozempic. In terms of patient reach, Januvia serves more beneficiaries (1,560,000 vs 1,180,000).
Year-over-year spending changed -12.3% for Januvia and +72.5% for Ozempic. Ozempic saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Januvia patent expires Jul 17, 2026. Ozempic patent expires Sep 20, 2031.
Frequently Asked Questions
Januvia is cheaper at $219.00 per claim, compared to $685.00 for Ozempic. That makes Januvia about 68% less expensive per claim based on Medicare Part D data.
Yes, both Januvia and Ozempic are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Januvia patent expires Jul 17, 2026. Ozempic patent expires Sep 20, 2031.
Medicare Part D spent $2.7B on Januvia covering 1,560,000 beneficiaries, and $5.0B on Ozempic covering 1,180,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.